Curis, Inc. announced financial results for the three- and twelve-month periods ended December 31, 2025, reporting Q4 net income of $19.4 million ($1.23 per share) versus a $9.6 million net loss in Q4 2024, and full-year net loss of $7.6 million ($0.58 per share) versus $43.4 million in 2024. Updates included clinical data from lymphoma and leukemia trials and a January 2026 PIPE financing with up to $80.8 million in gross proceeds.
Key takeaways
Q4 2025 net income $19.4 million ($1.23/share basic and diluted) vs net loss $9.6 million ($1.25/share) in Q4 2024
FY 2025 net loss $7.6 million ($0.58/share basic and diluted) vs $43.4 million ($6.88/share) in 2024
Q4 2025 revenues $1.1 million vs $3.3 million in Q4 2024; FY 2025 revenues $9.4 million vs $10.9 million in 2024
Cash and cash equivalents $5.1 million as of December 31, 2025; 12.9 million shares outstanding
January 2026 PIPE financing closed with initial $20.2 million gross proceeds and up to additional $60.6 million from warrants exercisable at $0.75/share
100% ORR (5/5) in BTKi-naïve PCNSL patients and 37% ORR (7/19) in BTKi-experienced patients in TakeAim Lymphoma study